Dr. Anthony F. Martin, Ph.D.

Overview

On September 22, 2008, the Board of Directors of Molecular Insight Pharmaceuticals, Inc. appointed Anthony F. Martin, Ph.D. Class III director effective September 22, 2008. Anthony Martin has more than 20 years experience in providing life science and biotechnology companies counsel on a range of strategic, management and funding issues. He has also had substantial success in building early-stage life science companies and helping them gain access to capital, in both executive and non-executive capacities. Dr. Martin is currently Founder and Managing Partner of TMA Consultants, an organization that specializes in providing business planning and interim management for biotechnology companies. Dr. Martin has most recently served as Non Executive Director of Prelude Trust plc, an investment trust that specialized in early-stage, technology-based businesses; and as Chairman of NeuTec Pharma plc, playing a pivotal role in guiding the biopharmaceutical company to become listed on the AIM market in the United Kingdom and its subsequent sale to Novartis. Dr. Martin has also held senior positions in a number of well known life science businesses both in the United Kingdom and United States including: Managing Director of British Biotech Products Ltd, Chairman, President and CEO of Molecular Probes, President of Molecular Biology, Invitrogen Corporation, Chairman and CEO of AZUR Environmental, CEO of Celsis International plc, as well as senior leadership roles at Amersham International plc. Dr. Martin holds a Ph.D. in Immunology and a first class honors degree in Applied Chemistry from the Universities of Manchester and Huddersfield, UK. In addition, Dr. Martin is currently Chairman of Sphere Medical Holdings plc, Wound Solutions Ltd. and Safeguard Biosystems Holdings Ltd. With these additions, the Molecular Insight Board now numbers nine independent members. Inside members from Molecular Insight are David S. Barlow, Chairman and CEO and John W. Babich Ph.D., President and CSO. The Molecular Insight Board wishes to thank Jodie Emery of Boston based Conley & Company for conducting the searches.